Phosphoproteomic Analysis Identifies TYRO3 as a Mediator of Sunitinib Resistance in Metastatic Thymomas

Phosphoproteomic Analysis Identifies TYRO3 as a Mediator of Sunitinib Resistance in Metastatic Thymomas

Background: After initially responding to empiric radio-chemotherapy, most advanced thymomas (TH) and thymic carcinomas (TC) become refractory and require second-line therapy. The multi-target receptor tyrosine kinase (RTK) inhibitor, sunitinib, is one of the few options, especially in patients with...

Full description

Bibliographic Details
Main Authors: Stefan Küffer, Jessica Grabowski, Satoru Okada, Nikolai Sojka, Stefan Welter, Alexander von Hammerstein-Equord, Marc Hinterthaner, Lucia Cordes, Xenia von Hahn, Denise Müller, Christian Sauer, Hanibal Bohnenberger, Alexander Marx, Philipp Ströbel
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Cancers
Subjects:
phosphoproteomics
sunitinib
TYRO3
drug response
biomarker
thymoma
Online Access:https://www.mdpi.com/2072-6694/14/19/4762

Internet

https://www.mdpi.com/2072-6694/14/19/4762

Similar Items